Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ohno

Showing results (351-360 of 400) with videos related to

Pageof 40
Sort By:
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis|May 5, 1999
Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary reportT Hosokawa, K Hamaguchi, R Tomioka, et al.
Blood|August 1, 1997
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acidT Tobita, A Takeshita, K Kitamura, et al.
Journal of Endocrinological Investigation|December 19, 2023
Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitusY Suzuki, H Kaneko, A Okada, et al.
Leukemia|May 28, 2005
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cellsA Takeshita, K Shinjo, K Naito, et al.
International Journal of Hematology|October 1, 1996
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study GroupY Kagami, Y Ariyoshi, A Horiuchi, et al.
Leukemia|March 21, 2003
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cellsA Takeshita, K Shinjo, K Naito, et al.
International Journal of Hematology|February 24, 2001
Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acidK Shinjo, A Takeshita, K Ohnishi, et al.
Early Human Development|August 11, 2000
Stressful delivery influences circulating thrombopoietin (TPO) levels in newborns: possible role for cortisol in TPO-mpl bindingK Ikeno, K Koike, A Takeshita, et al.
The American Journal of Gastroenterology|July 16, 1999
Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosisT Kawasaki, A Takeshita, K Souda, et al.
Leukemia|April 17, 2009
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cellsA Takeshita, N Yamakage, K Shinjo, et al.
Pageof 40

Showing results (351-360 of 400) with videos related to

Sort By:
Pageof 40
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis|May 5, 1999
Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary reportT Hosokawa, K Hamaguchi, R Tomioka, et al.
Blood|August 1, 1997
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acidT Tobita, A Takeshita, K Kitamura, et al.
Journal of Endocrinological Investigation|December 19, 2023
Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitusY Suzuki, H Kaneko, A Okada, et al.
Leukemia|May 28, 2005
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cellsA Takeshita, K Shinjo, K Naito, et al.
International Journal of Hematology|October 1, 1996
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study GroupY Kagami, Y Ariyoshi, A Horiuchi, et al.
Leukemia|March 21, 2003
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cellsA Takeshita, K Shinjo, K Naito, et al.
International Journal of Hematology|February 24, 2001
Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acidK Shinjo, A Takeshita, K Ohnishi, et al.
Early Human Development|August 11, 2000
Stressful delivery influences circulating thrombopoietin (TPO) levels in newborns: possible role for cortisol in TPO-mpl bindingK Ikeno, K Koike, A Takeshita, et al.
The American Journal of Gastroenterology|July 16, 1999
Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosisT Kawasaki, A Takeshita, K Souda, et al.
Leukemia|April 17, 2009
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cellsA Takeshita, N Yamakage, K Shinjo, et al.
Pageof 40